The Depo-Provera lawsuit is for women who developed brain tumors after at least two injections of the birth control shot. Growing scientific evidence suggests prolonged use of the drug may increase the risk of developing meningiomas, a type of brain tumor. Women suing Pfizer allege the manufacturer failed to adequately warn them about this increased risk. This article is for women considering filing a lawsuit. We explain how these lawsuits work and what to expect from a potential settlement.
If you or a loved one were diagnosed with meningioma after use of Depo-Provera or Depo-SubQ Provera, you may be eligible for compensation. Fill out the form to get a free case review.
Recent studies suggest a link between Depo-Provera and meningioma, a type of brain tumor. This new evidence is leading hundreds of women to file lawsuits against the drug’s manufacturer, Pfizer.
These lawsuits allege that Pfizer knew or should have known about the increased risk of meningiomas associated with the drug but didn’t disclose it to patients or doctors, causing financial losses for women who developed brain tumors. Women claim that if they had been properly warned, they would have opted for a different birth control method.
Filing lawsuits can help people affected seek compensation for lost wages, medical expenses, pain and suffering, and other damages. If you’ve been affected, we’ll explain your legal options at no cost and with no obligation.
Drugwatch works with a network of experienced attorneys to ensure every case gets the attention and strength it deserves. Our partners in this litigation filed the first federal lawsuit and successfully petitioned for multidistrict litigation (MDL) to reduce legal costs and raise the chance of fair settlements.
Explore your options
Diagnosed with meningioma after using Depo-Provera? Click the button below or call (866) 590-2452 for a free case review.
Depo-Provera cases are primarily product liability lawsuits against Pfizer. The legal case is based on claims of failure to warn, negligence and negligent design.
The plaintiffs are women who developed brain tumors after using the shot for birth control or conditions like endometriosis and uterine fibroids. They are seeking financial compensation for medical expenses, lost wages, pain and suffering, and other damages. Evidence in the lawsuits include medical records, use history and expert opinions linking the shot to brain tumors.
Pfizer is the defendant. Generic manufactures Pharmacia & Upjohn Company LLC, Greenstone LLC, A-S Medication Solutions, Prasco Laboratories and Preferred Pharmaceuticals Inc. are also named in lawsuits.
The statutes of limitations, or filing deadlines, for legal claims related to drug injuries vary by state. The period to file a lawsuit typically starts when you’re diagnosed with a brain tumor or could reasonably attribute it to your birth control.
This is a relatively new lawsuit, and the number of cases is growing as women are learning about it. If you believe the drug caused your health issues, you may have grounds for legal action.
Cases in federal court have been transferred to a multidistrict litigation (MDL) under Judge M. Casey Rodgers in Florida. The MDL exists to streamline the legal process for cases from all over the country. You do not need the be from Florida to join the lawsuit.
To qualify, you must prove you used Depo-Provera, Depo-SubQ Provera or an authorized generic version, and then developed a meningioma. You may not qualify if you took the shot only once or if you developed a brain tumor before your first injection.
Eligibility may also depend on how long ago you were diagnosed. Each state has a different deadline for filing.
How To Determine If You Have a Case
Medical Diagnosis: Confirm a connection between the drug and your health issues.
Legal Consultation: Speak with a product liability lawyer to review your case and understand your legal options.
Documentation: Gather prescriptions, treatment notes and all relevant medical records to support your claim.
“If you’ve been diagnosed with a meningioma after using Depo-Provera or Depo-SubQ Provera or their generic equivalents, you may qualify for a lawsuit,” said attorney Brendan Smith, a partner at Simmons Hanly Conroy in the Complex Litigation Department. “Consulting a qualified attorney can help determine if your case meets the specific legal and medical requirements for filing a claim.”
Potential Settlement Amounts for Brain Tumor Lawsuits
It’s too early to predict what the average Depo-Provera lawsuit settlement could be. Some lawyers may make estimations based on past litigation.
Pharmaceutical product liability cases can reach five- to six-figure settlements. Exact settlement amounts can vary depending on the specific circumstances of each case. The claims listed in lawsuits play a big role.
Manufacturers have faced lawsuits over multiple birth control methods. Some past cases have resulted in big payouts.
In 2020, Bayer settled 90% of 39,000 Essure claims for $1.6 billion.
Yaz and Yasmin lawsuits ended in sizable settlements for women. Bayer agreed to pay $2.04 billion to settle about 10,300 claims for blood clot injuries. The company also agreed to pay $21.5 million to settle 7,200 claims for gallbladder injuries and $56.9 million to settle about 1,200 claims involving strokes and heart attacks.
Note: Settlement figures and outcomes can vary greatly from one case to another. Always consult with a qualified attorney for the most accurate, up-to-date information.
Has Anyone Won a Depo-Provera Settlement or Verdict?
No, none of the recent brain tumor lawsuits have gone to trial. A settlement to end the lawsuits hasn’t been announced.
In the early 2000s, some women filed bone loss lawsuits. But there were no notable settlements or jury verdicts in the U.S. for those cases.
What Compensation Can You Seek?
The lawsuits seek compensation for “severe physical pain, mental suffering, inconvenience, and loss of the enjoyment of life.” You can also seek a payout to cover costs like medical expenses or lost earnings.
“Meningioma symptoms often significantly disrupt plaintiffs’ lives, leading to chronic pain, vision impairment, fatigue and cognitive difficulties,” Smith said. “These challenges can hinder work, relationships and daily activities.”
How Would a Settlement Work?
The lawsuits are being handled as an MDL, not a class action. The distinction is important to understand how a settlement would work.
When a class action ends, the settlement applies to all class members. But with an MDL, each case is considered separately. The individual payouts are based on the severity of the injuries in each case.
Several key factors could influence a settlement, including the number of injections, tumor size and location, medical expenses, lost wages, and pain and suffering.
Number of Injections
Research links long-term Depo-Provera use to a higher risk of developing meningioma. We are accepting cases of women who received at least two injections. But the longer someone used the drug, the easier it may be to demonstrate a link between their tumor and the shot. A stronger link could allow lawyers to negotiate a larger payout.
Type of Tumor
A tumor that forms in the head is more likely to result in a larger settlement because it strengthens the claim that the drug caused it. The tumor’s size and how it affects brain function can also impact the payout. Legal and medical experts may use tumor pathology, treatment records and scientific studies to support the link.
Medical Expenses
A portion of the payout from a product liability lawsuit is usually meant to cover medical expenses. Routine brain scans, surgery and radiation are common treatments for meningioma. And the medical expenses can amount to tens of thousands of dollars.
Lost Wages
A payout may be higher if you’ve missed work because of your tumor. A lost wages settlement can also account for future lost income if you’re permanently disabled from the tumor.
“I tried to go back to work after my surgery,” Edie R., who filed a brain tumor lawsuit, told Drugwatch. “I started with temp jobs, and I went backwards. It was too hard on me. It drained me.”
Pain and Suffering
How much pain your tumor has caused you can play a role in the payout you receive. Meningioma symptoms can range from manageable to life-altering. Some women whom Drugwatch has spoken to had catastrophic complications from their condition. These issues heavily impacted day-to-day life. Those who have experienced the most serious and debilitating impacts may receive larger payouts.
“My life has become overwhelming,” T.C., who filed a brain tumor lawsuit, told Drugwatch. “This diagnosis has only added to the burden, and it’s not something I can escape or ignore. It’s made everything harder.”
How To File a Depo-Provera Shot Lawsuit
Drugwatch can match you with an experienced product liability lawyer from our trusted network. All you have to do is sign up for a free case review.
After you fill out a form, we will contact you to ask a few questions about your Depo use. Then, we will let you know how we can help.
Eligibility Questions a Lawyer May Ask
Did you use Depo-Provera, an authorized generic version of the drug or Depo-SubQ Provera 104?
When did you first use the drug and for how long?
When were you diagnosed with a meningioma?
What treatment have you undergone related to your meningioma?
“People should expect to provide their medical history, including their usage of Depo-Provera and any history of pregnancy and other hormonal contraceptive use, as well as diagnosis and treatment information related to their meningioma,” Smith said.
The time limit for filing a legal claim will vary depending on where you live. So, it’s important to speak with an attorney about a potential claim as soon as possible.
What Are the Statutes of Limitation for Depo-Provera Lawsuits?
The statute of limitations for Depo-Provera lawsuits is typically two to three years from the time you’re diagnosed with a brain tumor. But, in some states, you may have only one year to file a lawsuit.
By definition, the statute of limitations is a deadline. It determines how long you have to file a lawsuit for a meningioma brain tumor caused by the birth control shot.
Other factors, such as the discovery rule, innovator liability, pharmaceutical immunity statute and statute of repose, could also affect whether you can file a lawsuit in your state.
The discovery rule may apply in some states. It could extend your deadline to file a lawsuit.
The countdown to file a lawsuit usually starts from the date you’re diagnosed with the tumor. But under the discovery rule, the clock starts ticking at the point where you could reasonably connect the tumor to your Depo-Provera use.
Lawyers may argue that their clients couldn’t reasonably connect the drug to their tumor without a warning on the drug’s label. Pfizer has yet to add a meningioma warning to the drug’s labels in the United States.
Innovator Liability
California and Massachusetts provide a way for people to sue a brand-name drug company if a generic version of the drug harms them. This is a legal concept known as innovator liability.
One reason for innovator liability is the “duty of sameness.” Under this law, generic drugs have to have the same labels as their brand-name counterparts, with few exceptions. So, if a label causes someone harm, then the brand-name company is responsible even if the person used a generic version.
Pharmaceutical Immunity Statute
Some states have immunity laws that could make it harder for you to file a lawsuit. These are sometimes called pharmaceutical immunity statutes.
We sometimes do not accept cases from Texas, for example, because of its pharmaceutical immunity statute.
In Texas, the drug’s FDA-approved label plays a big role. Drug makers aren’t liable for claims that they didn’t warn of a side effect if the drug’s warnings are FDA-approved.
So, since the FDA-approved label doesn’t mention tumors, it may be difficult to claim in Texas that Pfizer legally failed to warn customers.
Statute of Repose
Some states have a statute of repose. These laws set a deadline for filing a lawsuit that is not based on when your injury occurred or was discovered, but from a specific event like the initial sale of the product.
Depending on where you live, statutes of repose could affect your ability to file a lawsuit. Texas, for example, has a statute of repose that is 15 years from the date of sale. So, this could bar you from filing a lawsuit in Texas if you used the drug decades ago.
Women Who Have Filed Depo-Provera Lawsuits
Tina Thomas was diagnosed with a meningioma after using Depo-Provera.
T.C. received Depo-Provera shots for three years and was diagnosed with a meningioma brain tumor. She said she lives in a constant state of worry that the tumor might grow. “I was told how great Depo-Provera was, and I thought it would be more reliable and convenient since I wouldn’t have to take it daily,” she said. “I had no idea it would lead to such serious health problems.” T.C. learned lawyers were filing lawsuits, and she had her case reviewed. She is one of the hundreds of women who have filed a lawsuit. Read T.C.’s Story.
Depo-Provera user Tina Thomas needed surgeries and radiation treatments for her meningioma. She couldn’t work for months. When she learned a connection may exist between the birth control shot and her tumors, she was angry. “You mean to tell me that they knew about this and they’re still giving these shots to women?” Thomas said. “They just did not value our lives at all.”
Edie R. started Depo shots decades ago to help manage scar tissue that formed inside her uterus. She suffered from meningioma symptoms and constant seizures. She had a craniotomy to remove her tumor. But nearly every other symptom that she had worsened after the procedure. “I had to quit my job. I couldn’t do it anymore,” she said. “The financial devastation has been enormous in lost earnings.”
Depo-Provera: A Convenient Shot, But at What Cost to Women’s Health?
Depo-Provera, marketed as a safe and convenient birth control option, is used by millions of women. But alarming personal stories and growing research suggest it may have come with severe hidden costs.
We are closely monitoring the Depo-Provera litigation to bring you the latest updates and news as developments happen. Check back here regularly to stay informed.
June 6, 2025: Women Report Meningiomas in Birth Control Survey
Multiple women who took part in a new Drugwatch survey on birth control reported that they developed meningiomas as a side effect. These are the brain tumors that have been tied to Depo-Provera usage. That possible connection is at the heart of the litigation. Among women who took part in the survey, seven said that they developed these tumors.
“Plaintiffs generally allege that they developed meningiomas—sometimes multiple tumors—after extended use of Depo-Provera,” Smith said.
Nearly 20% of respondents who have taken birth control said that they have used an injection like Depo.
June 5, 2025: Potential Litigation Hurdles
Pfizer has argued that plaintiffs’ failure to warn claims are invalid because the company submitted a drug label change with a warning that the FDA didn’t approve, an issue called preemption. However, plaintiffs’ lawyers are confident they have an argument against this. Plaintiffs are also in the middle of proving that there’s sufficient evidence that connects the drug to intracranial meningiomas. Discovery is also ongoing.
June 2, 2025: MDL Continues To Grow
The number of Depo lawsuits grouped together in federal court continues to grow. At the start of this month, there were 348 active cases in the MDL. This is a jump of nearly 60 cases from this time last month. Expect that growth to continue in the coming months as more lawsuits are filed.
There has also been a slight update to the case management conference schedule in the MDL. The June conference has been canceled. The next case management conference will now be on July 11.
May 27, 2025: Case Management Conference Approaches
It is almost time for the May case management conference for hundreds of Depo-Provera lawsuits grouped together in multidistrict litigation. This is a meeting where both sides of the litigation and the court discuss outstanding issues to help keep the lawsuits moving forward. The agenda for this month’s meeting includes updates on the early progress of these lawsuits. Pfizer has already produced more than 10 million pages of documents. Also on the agenda is an update to the status of Depo lawsuits outside the MDL. 72 additional cases are pending across several different state courts, with most of these in New York.
May 23, 2025: Federal Judges to Consider Adding Case to Growing MDL
A panel of federal judges is scheduled to meet on May 29, 2025, at 11 a.m. to decide whether to add Vicki Daniels’s lawsuit to the MDL in Florida. The MDL currently sits at 289 cases.
May 12, 2025: Identifying Deficiencies in Plaintiffs’ Complaints
A new order has set guidelines for finding deficiencies in plaintiffs’ complaints. According to the order, complaints have to include several key details from plaintiffs. This includes their injury, how that injury resulted from Depo and the citizenship of both the plaintiff and defendant. All complaints filed in the MDL so far will be evaluated to see if they include all these factors.
May 6, 2025: Court Outlines Documentation Process
Work continues in the MDL. A new court order has outlined the plaintiff documentation process. Plaintiffs must submit proof of use information, such as documentation that they used the drug. They also have to show documentation of their injuries and diagnoses. The court said that it will speak with the parties in the MDL to discuss concerns involving plaintiffs who used the drug so long ago that they may not have documentation.
May 1, 2025: MDL Grows By 159 New Cases
Major growth continues in the MDL as new lawsuits continue to be filed. At the start of April, 130 cases were consolidated in federal court. That number jumped to 289 at the beginning of May, more than doubling the size of the litigation. Expect that number to continue to rise in the coming months.
April 21, 2025: Court Considers Who Will Be Defendants in the MDL
A new order has provided some clarity on where some of the defendants stand. Greenstone, Viatris and Prasco have all been named as defendants in lawsuits. But the court noted “some confusion” over whether they had enough involvement with the drug. It now looks like Prasco will likely be dismissed from the litigation. Greenstone and Viatris will remain part of the MDL.
April 7, 2025: Judge Threatens Future Sanctions After Companies Miss Key Deadline
Some early contention in the MDL has been resolved. The court had set a deadline for generic manufacturers to declare they were not involved. Defendants Greenstone and Viatris failed to do so by the set date. The court ordered them to show cause for their failure to do so. The companies have since submitted those documents. The court also cautioned that they may be sanctioned if they continue to fail to respond to court orders.
April 3, 2025: Judge Schedules Key Case Management Conferences Throughout 2025
The MDL continues to move at a solid pace. Case management conferences have been scheduled throughout 2025. These conferences are a key part of the MDL process. They set times for the parties to meet and check in on the litigation’s progress.
Case Management Conference Schedule
Date
Time
May 30, 2025
9 a.m. CST
June 27, 2025
9 a.m. CST
July 18, 2025
1 p.m. CST
August 22, 2025
9 a.m. CST
September 26, 2025
9 a.m. CST
October 24, 2025
9 a.m. CST
November 21, 2025
9 a.m. CST
December 19, 2025
9 a.m. CST
April 1, 2025: Number of Lawsuits Up 66% From Last Month
The newly formed MDL has seen some solid growth in its first full month. At the start of March, 78 lawsuits had been consolidated into the MDL. As of April 1, the number of active cases has ballooned to 130 as dozens of new lawsuits were added. That growth may continue as the litigation gets underway.
March 16, 2025: Court Chooses Drugwatch Legal Partners for MDL Leadership Roles
Leadership positions have been selected in the MDL. The team consists of three members. They are tasked with leading and coordinating the activities of all plaintiffs’ attorneys.
March 15, 2025: Pilot Cases Can Give Insight Into Settlement Amounts and Trial Strategies
The court approved a schedule that sets discovery for five pilot cases. The schedule begins on March 27 and runs through March 2026. During discovery, both sides exchange evidence and information to prepare for trial. Pilot cases are a select group of cases chosen early in the legal process to serve as test cases for the entire MDL. Judge M. Casey Rodgers chose five pilot cases to address key legal questions. The decisions can then be applied to the remaining cases. The result is a faster process and resolution. Pilot cases can weigh heavily on settlement negotiations and trial strategies. But the results of the pilot cases don’t apply to all cases in the MDL. Each case still needs to be considered individually.
Discovery Schedule
Date
Event
March 13, 2025
Deadline for Pilot Case Plaintiffs to File Amended Complaints
March 27, 2025
Discovery Opens
March 27, 2025
Defendants to Answer and Serve 26(a)(1) Disclosures in Pilot Cases
May 11, 2025
Defendants’ Certification of Completion of Document Production on Preemption and General Causation
July 25, 2025
Close of Preemption Discovery
August 24, 2025
Motions for Summary Judgment Regarding Preemption to be Filed
September 23, 2025
Opposition to Preemption MSJs to be Filed
September 23, 2025
Close of General Causation Fact Discovery
September 30, 2025
Replies in Support of Preemption MSJs, if Requested by Defendants and Permitted by Court
October 23, 2025
Plaintiffs’ General Causation Expert Disclosures
November 22, 2025
Defendants’ General Causation Expert Disclosures
January 10, 2026
Deadline for Depositions of All General Causation Experts
February 10, 2026
Rule 702 Motions Regarding General Causation Experts to be Filed
March 12, 2025
Oppositions to Rule 702 Motions to be Filed
March 19, 2026
Replies in Support of Rule 702 Motions to be Filed, if Requested by Movants and Permitted by Court
February 2025: Fast Start to New MDL in Unexpected Florida Court
A federal judicial panel transferred 27 cases from eight districts to the Northern District of Florida. The panel assigned them to Judge M. Casey Rodgers. These cases are now consolidated for pretrial proceedings. Another 41 related cases were also pending in fifteen districts.
“The Northern District of Florida is an appropriate transferee district for this litigation," the panel wrote in its order. "Two related actions are pending in this district, which offers the necessary judicial resources and expertise to manage this nationwide litigation in an efficient and convenient manner. Judge M. Casey Rodgers, to whom we assign this MDL, is an able jurist with extensive and exceptional experience presiding over large product liability MDLs. We are confident that she will steer this litigation on a prudent and expeditious course."
The newly formed MDL got off to a fast start. Judge Rodgers took a somewhat unusual and expedient approach to the litigation. She immediately selected five “pilot” cases from the group of lawsuits. The five cases will proceed through discovery and trial. They essentially serve to represent the MDL. “The work of the MDL will be accomplished through the Pilot cases,” Judge Rodgers said in her order.
January 2025: Pfizer Agrees MDL Makes Sense, Disagrees on Location
January was a key month, with a hearing on the creation of an MDL held on Jan. 30. Pfizer agreed that an MDL makes sense. But it disagreed with lawyers representing Depo users on where the MDL should be located. They prefer California as the state would allow generic drug users to bring cases against Pfizer.
December 2024: MDL Panel Quickly Schedules Hearing, Signals Urgency of Claims
The MDL panel set a hearing for the end of January on whether to centralize Depo-Provera lawsuits in an MDL. The panel announced the hearing less than a month after the motion to create an MDL was filed. “In this instance, the quick scheduling could indicate that the panel recognizes the urgency and importance of the claims at hand, which is a positive sign for plaintiffs seeking coordination,” Smith told Drugwatch in a recent article on where the litigation is headed in 2025. “In 2025, we will likely see the development of an MDL, a consolidation of cases and initial rounds of discovery exchanged between the parties.” In an opposition response, Pfizer claims that it decided to change the drug's label to mention the possible tumor risk after it learned of the new study. But the company says that the FDA rejected this label change.
November 2024: A Push for MDL to Streamline Legal Process
Drugwatch’s legal partner Weitz & Luxenberg filed a motion to group Depo-Provera lawsuits into multidistrict litigation. “Consolidation into an MDL involves transferring related cases to a single federal court,” Smith said. “This process can make litigation more efficient, as discovery and pretrial rulings apply to all cases. For individuals, it means streamlined case handling and a strong likelihood of reduced case costs.”
A November court document showed lawsuits were pending in eight districts. Lawyers expect case numbers to rise because of the large number of people who have used the drug over the years. An MDL is a way for the federal courts to handle these related cases. With an MDL, cases are centralized in one court, under a single judge for pretrial proceedings. Lawyers representing affected women want the cases transferred to California or Massachusetts. The laws in these states allow people to sue generic manufacturers. It would open the door for lawsuits involving authorized generic versions of the drug. Generic manufacturers include:
Pharmacia & Upjohn Company LLC
Greenstone LLC
A-S Medication Solutions
Prasco Laboratories
Preferred Pharmaceuticals Inc.
Unlike in a class action lawsuit, each case in an MDL remains separate. If there's a settlement, each individual will receive a payout based on the extent and nature of their injuries. According to the motion, “most of the plaintiffs who have filed suit underwent intracranial surgery, with many women being left with seizure disorders, vision loss, and other permanent neurological injuries.”
October 2024: Women File First Depo-Provera Lawsuits
Monique Jones became one of the first women to file a Depo-Provera lawsuit. “Ms. Jones is seeking compensation for her injuries relating to the development of a cerebral meningioma which was caused by her usage of Depo-Provera,” Brendan McDonough, an attorney named to the Science and Experts Subcommittee, told Drugwatch. “We believe Pfizer and others knew for many years about the risk of developing meningioma associated with Depo-Provera.” Jones' doctors are unwilling to perform surgery. Her lawsuit says it would be highly invasive and risky given how calcified her tumor is and where it is located in her brain. She will continue to live with the symptoms and side effects of the tumor. Her symptoms include headaches, blurred vision and vertigo, according to the complaint.
September 2024: Another Study Strengthens Evidence That Depo Causes Meningioma Tumors
Another study links Depo to an increased meningioma risk. A researcher from the University of Alabama at Birmingham wanted to investigate U.S. data. The previous study published in March was based on a smaller sample size of women from France. His research found that the drug increased the risk of cerebral meningioma. This study, published in the peer-reviewed journal Cancers, strengthens the evidence that the drug may be tied to the development of tumors. The association became stronger with prolonged use. Lawyers have included this study in their evidence.
April 2024: Pfizer Addresses Study’s Findings
Pfizer has responded to the new study that shows a link between Depo-Provera and tumors. The drug manufacturer said in a statement that “We are aware of this potential risk associated with long-term use of progestogens and, in collaboration with regulatory agencies, are in the process of updating product labels and patient information leaflets with appropriate wording.”
March 2024: New Scientific Study Links Depo Shot to Meningioma Risk
March 2024: A new study found that women who got the Depo shot had a 5.6-fold higher risk of developing a meningioma. French researchers published their findings in The BMJ. Soon after the study was published, lawyers began investigating lawsuits.
Depo-Provera Is an Injectable Birth Control; Depo-SubQ Provera 104 Is Also an Endometriosis Treatment
Depo-Provera hit the U.S. market more than 30 years ago. It was the first female birth control option to be advertised on TV. It became a popular choice for women as it was marketed as a safe and effective drug.
About 1 in 4 sexually experienced women have used the shot at some point, according to a CDC report. The report cited data from 2015 to 2019.
Did You Know?
Depo-Provera is a birth control injection that contains the progestin hormone.
Depo-SubQ Provera 104 is used for birth control and to treat endometriosis.
Endometriosis typically affects your ovaries, fallopian tubes and tissue lining your pelvis. Tissue grows outside the uterus, causing pelvic pain and other symptoms.
But recent research found that alarming health issues may be tied to the shot. A March 2024 study published in the BMJ found that Depo users are at a much higher risk of developing a meningioma.
Women are filing lawsuits because they developed tumors after using the shot. They argue that Pfizer knew or should have known about the risk and did not adequately warn them.
“I was told how great Depo-Provera was, and I thought it would be more reliable and convenient since I wouldn’t have to take it daily,” T.C. said. “I had no idea it would lead to such serious health problems.”
Pfizer Did Not Warn Women of Brain Tumor Risk
Lawsuits argue that Pfizer’s negligence exposed women to significant health risks. Women who took Depo say that they would have chosen a different birth control if they had known of the tumor risk.
“Defendants ignored reports from patients and health care providers throughout the United States which indicated that Depo-Provera failed to perform as intended,” lawsuits state. “…Defendants continued to falsely and misleadingly market Depo-Provera as a safe and effective prescription drug for contraception and other indications.”
Failure To Warn
In the U.S., Depo-Provera labels don’t include meningioma warnings, unlike labels in the United Kingdom and European Union that do mention meningiomas.
Lawsuits argue Depo-Provera’s design uses a high dose of progesterone, not necessary for effective contraception, creating an unreasonable risk of meningioma.
Lawsuits also claim defendants’ marketing falsely represented the shot to be a safe and effective contraceptive option with no increased risk of meningioma.
The U.S. label includes information on side effects. It also features a black box warning related to bone density. But lawsuits say that it does not mention the risk of meningioma.
This isn’t the case in other parts of the world.
Lawsuits say Depo labels in the United Kingdom and European Union now mention the tumors. The EU label even warns patients to tell their doctor if they have a history of meningioma.
Labels for the drug in Canada have also referenced meningiomas since at least 2015.
“Defendants knew or should have known for decades that Depo-Provera, when administered and prescribed as intended, can cause or substantially contribute to the development of meningiomas,” lawsuits state.
Early Studies Signal Pfizer Knew of Depo-Provera Dangers
The study published in The BMJ in 2024 found that the Depo shot raised the risk of meningiomas by more than five times. That risk increased with one year or more of use.
These lawsuits stem from that new study. But evidence has existed for decades that the drug’s ingredients could be tied to tumors.
“We believe Pfizer and others knew for many years about the risk of developing meningioma associated with Depo-Provera,” McDonough said.
“The [study] recently published in BMJ is the first to assess the risk associated with progestogens that are much more widely used for multiple indications, such as contraception.”
Depo-Provera is known chemically as medroxyprogesterone acetate. It contains the hormone progestin, a synthetic version of naturally occurring progesterone. Past research has linked this type of hormone to meningiomas.
A 1986 study found that meningiomas contain a high number of progestin receptors. This suggests a potential connection between hormone levels and the development of these tumors.
Progestogen Medications and Brain Tumors: What You Need to Know
“The signature injury is cerebral meningioma, which is a tumor of the meningeal lining of the brain that can press on sensitive brain structures and cause severe problems including seizures, headaches, vision loss, and even death,” Smith said.
Meningiomas are not true brain tumors because they don’t start in brain tissue. They form in the membranes covering the brain and spinal cord. But they’re often referred to as brain tumors in the medical community.
Meningiomas are the most common tumors that form in the head and are often benign. But they can still cause serious health problems.
They can grow and put pressure on nearby brain tissue and structures. Patients often need invasive surgery or radiation treatment, which can cause brain injury.
“The signature injury is cerebral meningioma, which is a tumor of the meningeal lining of the brain that can press on sensitive brain structures and cause severe problems including seizures, headaches, vision loss, and even death.”
One lawsuit said that Kathleen Fazio had surgery to remove a tumor after taking the drug for years. Complications from that surgery left her with blurred and double vision. Her senses of taste and smell diminished as well.
Patients Describe Life-Altering Meningioma Symptoms in Lawsuits
Meningiomas can grow unnoticed until they are large enough to press on your brain. Symptoms of meningiomas mentioned in lawsuits include headaches and vision issues.
Meningioma Symptoms Include
Changes in behavior or personality
Headaches that may get worse over time
Loss of smell
Nausea
Seizures
Trouble thinking clearly or brain fog
Trouble walking
Vision or hearing loss, including ringing in the ears
Weakness in a leg or arm
Other symptoms include aphasia, memory loss and trouble speaking.
T.C. told Drugwatch that “dealing with the side effects was brutal.”
“Don’t ignore what’s happening to you,” T.C. said. “These side effects aren’t just something to push through — they can be life-changing. Make sure you’re getting checked and take action now. If I’d known what I was facing, I would have sought help sooner.”
Common Questions About Depo-Provera Lawsuits
More than 4,800 people have reached out to Drugwatch to learn more about Depo-Provera lawsuits and explore their legal options. We’ve answered the top three questions we get most often here.
Women who have experienced serious side effects from Depo-Provera may qualify for a lawsuit against the manufacturer. If you've suffered long-term health issues that you believe were caused by the birth control shot, you may be eligibile to sue for compensation.
Estimated settlement amounts for a Depo-Provera lawsuit range from $100,000 to over $1 million. However, the exact payout will depend on the circumstances of each case and may be well beyond these estimates. Settlements are calculated based on the severity of injuries, medical costs, lost wages, pain and suffering, and the overall impact to quality of life.
A sceintific study published in 2024 found a 5.6 times increased risk of intracranial meningioma (brain tumor) requiring surgery in women using Depo-Provera. Meningiomas can cause serious health problems, including headaches, vision problems and seizures.
In a recent Q&A with Drugwatch, we asked Smith what advice he would give to women considering filing a lawsuit.
“Gather all medical records that you can, including Depo-Provera prescriptions and diagnosis of meningioma,” he said. “Consult an attorney experienced in pharmaceutical litigation to evaluate your case and guide you through the process.”
Drugwatch Helping Women Connect with a Trusted Lawyer Today
We are investigating product liability cases that claim Depo-Provera causes brain tumors. If you were diagnosed with a meningioma after at least two injections, call (866) 590-2452. Or request a free case review online.
Our partners have won more than $19 billion in verdicts and settlements and have spent decades taking on companies like Johnson & Johnson, Bayer and Pfizer. They’ve handled lawsuits against DES, the Ortho Evra patch, Yaz and Yasmin. They can explain your legal options to you.
Please seek the advice of a medical professional before making health care decisions.
We appreciate your feedback. One of our content team members will be in touch with you soon.
We appreciate your feedback. One of our content team members will be in touch with you soon.
Who Am I Calling?
Calling this number connects you with a Drugwatch.com representative. We will direct you to one of our trusted legal partners for a free case review.
Drugwatch.com's trusted legal partners support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.